Powered by

Lilly's under-pressure Trulicity scores with first-of-its-kind cardio outcomes win

Nov 06, 2018 - FiercePharma

All eyes are on Eli Lilly's Trulicity as it faces down some hefty new competition from diabetes rival Novo Nordisk. But the Indianapolis drugmaker just notched an important trial win that shows it can hang with its rival.

Monday, the pharma giant said that in a cardiovascular outcomes trial, Trulicity showed it could significantly cut down the combined rate of heart attack, stroke and cardiovascular death. It's not the first drug to gain that distinction; fellow Lilly drug, SGLT2 Jardiance...